Anang A. Shelat, PhD
Anang A. Shelat, PhD

Anang A. Shelat, PhD

Associate Member, St. Jude Faculty

  • Director, Lead Discovery Informatics and Compound Management



BA – Harvard University
 – University of California, San Francisco, California

Research Interests

  • Translational research in pediatric cancer
  • Development of novel and selective epigenetic drug therapies
  • Targeting the DNA damage response to optimize chemo- and  radiation therapy
  • Multi-scale modeling of biological and chemical data

Selected Publications

Twarog NR, Connelly M, Shelat AA. A critical evaluation of methods to interpret drug combinations. Sci Rep.  Mar 20;10(1):5144; 2020. doi: 10.1038/s41598-020-61923-1.

Gose T, Shafi T, Fukuda Y, Das S, Wang Y, Allcock A, Gavan McHarg A, Lynch J, Chen T, Tamai I, Shelat A, Ford RC, Schuetz JD. ABCG2 requires a single aromatic amino acid to "clamp" substrates and inhibitors into the binding pocket. FASEB J. Feb 17, 2020. doi: 10.1096/fj.201902338RR. [Epub ahead of print]

Drenberg CD, Shelat A, Dang J, Cotton A, Orwick SJ, Li M, Jeon JY, Fu Q, Buelow DR, Pioso M, Hu S, Inaba H, Ribeiro RC, Rubnitz JE, Gruber TA, Guy RK, Baker SD. A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML.Nat Commun. May 16;10(1):2189; 2019. doi: 10.1038/s41467-019-09917-0.

Loh A, Bradley C, Karlstrom A, Krafcik F, Dyer MA, Stewart E, Goshorn R, Chen X, Daryani V, Stewart C, Calabrese C, Funk A, Miller G, Shelat A, Bahrami A. Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations. Cancer Lett November 2018.

Stewart E, McEvoy J, Wang H, Chen X, Honnell V, Ocarz M, Gordon B, Dapper J, Blankenship K, Yang Y, Li Y, Shaw TI, Cho JH, Wang X, Xu B, Gupta P, Fan Y, Liu Y, Rusch M, Griffiths L, Jeon J, Freeman BB 3rd, Clay MR, Pappo A, Easton J, Shurtleff S, Shelat A, Zhou X, Boggs K, Mulder H, Yergeau D, Bahrami A,  Mardis ER,  Wilson RK,  Zhang J,  Peng J,  Downing JR,  Dyer MA. Identification of therapeutic targets in rhabdomyosarcoma through integrated genomic,  epigenomic,  and proteomic analyses. Cancer Cell 34(3):411-426.e19, 2018.

Nimmervoll BV, Boulos N, Bianski B, Dapper J, DeCuypere M, Shelat A, Terranova S, Terhune HE, Gajjar A, Patel YT, Freeman BB, Onar-Thomas A, Stewart CF, Roussel MF, Guy RK, Merchant TE, Calabrese C, Wright KD, Gilbertson RJ. Establishing a preclinical multidisciplinary board for brain tumors. Clin Cancer Res 24:1654-1666, 2018.

Bharatham N, Slavish PJ, Young BM, Shelat AA. The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors. J Mol Graph Model 81:197-210, 2018.

Shadrick WR, Slavish PJ, Chai SC, Waddell B, Connelly M, Low JA, Tallant C, Young BM, Bharatham N, Knapp S, Boyd VA, Morfouace M, Roussel MF, Chen T, Lee RE, Kiplin Guy R, Shelat AA, Potter PM. Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Bioorg Med Chem Nov 4, 2017.

Stewart E, Federico SM, Chen X, Shelat AA, Bradley C, Gordon B, Karlstrom A, Twarog NR, Clay MR, Bahrami A, Freeman BB 3rd, Xu B, Zhou X, Wu J, Honnell V, Ocarz M, Blankenship K, Dapper J, Mardis ER, Wilson RK, Downing J, Zhang J, Easton J, Pappo A, Dyer MA. Orthotopic patient-derived xenografts of paediatric solid tumours. Nature 549(7670):96-100, 2017.

Riniker S, Landrum GA, Montanari F, Villalba SD, Maier J, Jansen JM, Walters WP, Shelat AA. Virtual-screening workflow tutorials and prospective results from the Teach-Discover-Treat competition 2014 against malaria. F1000Res 6:1136, 2017.

Scott DC, Hammill JT, Min J, Rhee DY, Connelly M, Sviderskiy VO, Bhasin D, Chen Y, Ong SS, Chai SC, Goktug AN, Huang G, Monda JK, Low J, Kim HS, Paulo JA, Cannon JR, Shelat AA, Chen T, Kelsall IR, Alpi AF, Pagala V, Wang X, Peng J, Singh B, Harper JW, Schulman BA, Guy RK. Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase. Nat Chem Biol 13(8):850-857, 2017.

Smallwood HS, Duan S, Morfouace M, Rezinciuc S, Shulkin BL, Shelat A, Zink EE, Milasta S, Bajracharya R, Oluwaseum AJ, Roussel MF, Green DR, Pasa-Tolic L, Thomas PG. Targeting metabolic reprogramming by influenza infection for therapeutic intervention. Cell Rep 19(8):1640-1653, 2017.

Papadatos G, Burrows J. Shared consensus machine learning models for predicting blood stage malaria inhibition. J Chem Inf Model 57(3):445-453, 2017.

Twarog NR, Stewart E, Hammill CV, A Shelat A. BRAID: A unifying paradigm for the analysis of combined drug action. Sci Rep 6:25523, 2016.

Twarog NR, Low JA, Currier DG, Miller G, Chen T, Shelat AA. Robust classification of small-molecule mechanism of action using a minimalist high-content microscopy screen and multidimensional phenotypic trajectory analysis. PLoS One 11(2):e0149439, 2016.

Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grunewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Sarikas BR, Redini F, Richter GH, Rossig C, Schadler K, Schafer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Uren A, Zinovyev A, Delattre O. The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget Jan 18, 2016. Epub ahead of print. doi: 10.18632/oncotarget.6937.

Morfouace M, Cheepala S, Jackson S, Fukuda Y, Patel YT, Fatima S, Kawauchi D, Shelat AA, Stewart CF, Sorrentino BP, Schuetz JD, Roussel MF. ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy. Cancer Res 75(18):3879-89, 2015.

Gupte A, Baker EK, Wan SS, Stewart E, Loh A, Shelat AA, Gould CM, Chalk AM, Taylor S, Lackovic K, Karlström Å, Mutsaers AJ, Desai J, Madhamshettiwar PB, Zannettino AC, Burns C, Huang DC, Dyer MA, Simpson KJ, Walkley CR. Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clin Cancer Res 21(14):3216-29, 2015.

Stewart E, Federico S, Karlstrom A, Shelat A, Sablauer A, Pappo A, Dyer MA. The childhood solid tumor network: A new resource for the developmental biology and oncology research communities.Dev Biol Apr 9, 2015. Epub ahead of print. pii:S0012-1606(15)00060-3. doi:10.1016/j.ydbio.2015.02.002.

Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB 3rd, Bahrami A, Pappo A, Wu J, Loh A, Karlstrom A, Calabrese C, Gordon B, Tsurkan L, Hatfield MJ, Potter PM, Snyder SE, Thiagarajan S, Shirinifard A, Sablauer A, Shelat AA, Dyer MA. Targeting the DNA Repair Pathway in Ewing Sarcoma. Cell Rep 9(3):829-840, 2014.

Morfouace M, Shelat A, Jacus M, Freeman BB 3rd, Turner D, Robinson S, Zindy F, Wang YD, Finkelstein D, Ayrault O, Bihannic L, Puget S, Li XN, Olson JM, Robinson GW, Guy RK, Stewart CF, Gajjar A, Roussel MF. Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma. Cancer Cell 25(4):516-529, 2014.

Bharatham N, Bharatham K, Shelat AA, Bashford D. Ligand binding mode prediction by docking: mdm2/mdmx inhibitors as a case study. J Chem Inf Model 54(2):648-659, 2014.

Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, Wu G, Bradley C, McEvoy J, Pappo A, Spunt S, Valentine MB, Valentine V, Krafcik F, Lang WH, Wierdl M, Tsurkan L, Tolleman V, Federico SM, Morton C, Lu C, Ding L, Easton J, Rusch M, Nagahawatte P, Wang J, Parker M, Wei L, Hedlund E, Finkelstein D, Edmonson M, Shurtleff S, Boggs K, Mulder H, Yergeau D, Skapek S, Hawkins DS, Ramirez N, Potter PM, Sandoval JA, Davidoff AM, Mardis ER, Wilson RK, Zhang J, Downing JR, Dyer MA. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 24(6):710-724, 2013.

Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Feau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20(3):384-99, 2011.

Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH, Smithson DC, Connelly M, Clark J, Zhu F, Jimenez-Diaz MB, Martinez MS, Wilson EB, Tripathi AK, Gut J, Sharlow ER, Bathurst I, El Mazouni F, Fowble JW, Forquer I, McGinley PL, Castro S, Angulo-Barturen I, Ferrer S, Rosenthal PJ, Derisi JL, Sullivan DJ, Lazo JS, Roos DS, Riscoe MK, Phillips MA, Rathod PK, Van Voorhis WC, Avery VM, Guy RK. Chemical genetics of Plasmodium falciparum. Nature 465(7296):311-5, 2010.

Shelat AA, Guy RK. A road less traveled by: exploring a decade of Ellman chemistry. Bioorg Med Chem 17(3):1088-93, 2009.

Mallari JP, Shelat AA, Obrien T, Caffrey CR, Kosinski A, Connelly M, Harbut M, Greenbaum D, McKerrow JH, Guy RK. Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. J Med Chem 51(3):545-52, 2008.

Mallari JP, Shelat A, Kosinski A, Caffrey CR, Connelly M, Zhu F, McKerrow JH, Guy RK. Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorg Med Chem Lett 18(9):2883-5, 2008.

Shelat AA, Guy RK. Scaffold composition and biological relevance of screening libraries. Nat Chem Biol 3(8):442-6, 2007.

Shelat AA, Guy RK. The interdependence between screening methods and screening libraries. Curr Opin Chem Biol 11(3):244-51, 2007.

Fujii N, Shelat A, Hall RA, Guy RK. Design of a selective chemical probe for class I PDZ domains. Bioorg Med Chem Lett 17(2):546-8, 2007.

Last update: April 2020

For updates on COVID-19, please read.